A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis.

Pioglitazone, an oral anti-diabetic that stimulates the PPAR-gamma transcription factor, increased survival of mice with amyotrophic lateral sclerosis (ALS).We performed a phase II, double blind, multicentre, placebo controlled trial of pioglitazone in ALS patients under riluzole. 219 patients were...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Luc Dupuis, Reinhard Dengler, Michael T Heneka, Thomas Meyer, Stephan Zierz, Jan Kassubek, Wilhelm Fischer, Franziska Steiner, Eva Lindauer, Markus Otto, Jens Dreyhaupt, Torsten Grehl, Andreas Hermann, Andrea S Winkler, Ulrich Bogdahn, Reiner Benecke, Bertold Schrank, Carsten Wessig, Julian Grosskreutz, Albert C Ludolph, GERP ALS Study Group
Format:	Artigo
Jezik:	Inglês
Izdano:	Public Library of Science (PLoS) 2012-01-01
Serija:	PLoS ONE
Online dostop:	http://europepmc.org/articles/PMC3371007?pdf=render
Oznake:	Označite Brez oznak, prvi označite!